Large biopharma companies are partnering with companies developing drug candidates that harness induced proximity approaches to tackle challenging targets.

Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year to date, with many transactions focusing on Chinese assets.

Advances with in vivo cell therapies and adeno-associated viral vectors that deliver gene therapies to organs other than the liver have driven major deals in the past 12 months.

Powered by its industry-leading library of genomic data, covering a comprehensive spectrum of genes, Caris Life Sciences is committed to identifying the best treatments.

Saudi Arabia targets global biotech leadership by 2040 with a four-pillar strategy.

Xcell Therapeutics is developing completely animal-origin-free, chemically defined stem-cell media, enhancing safety, quality, and reproducibility.

The Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has been manufacturing and distributing high-quality therapeutics across the Middle East for four decades.

The biotech is aiming to develop a first-line consolidation treatment for large B-cell lymphoma that predicts and prevents relapse.

Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of transformative therapeutics in collaboration with biopharma partners across various high-need therapeutic areas.

ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications.

Powered by its industry-leading library of genomic data, covering a comprehensive spectrum of genes, Caris Life Sciences is committed to identifying the best treatments.

The Korea Drug Development Fund (KDDF), Korea’s largest non-dilutive funder of drug research and development (R&D), is advancing Korea’s oncology sector with a globally competitive, modality-diverse pipeline of cancer therapeutics.

By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.